TALICIA Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Talicia, and what generic alternatives are available?
Talicia is a drug marketed by Redhill and is included in one NDA. There are five patents protecting this drug.
This drug has twenty-nine patent family members in twenty-four countries.
The generic ingredient in TALICIA is amoxicillin; omeprazole magnesium; rifabutin. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; omeprazole magnesium; rifabutin profile page.
DrugPatentWatch® Generic Entry Outlook for Talicia
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 12, 2034. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TALICIA
International Patents: | 29 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TALICIA |
What excipients (inactive ingredients) are in TALICIA? | TALICIA excipients list |
DailyMed Link: | TALICIA at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TALICIA
Generic Entry Date for TALICIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE, DELAYED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for TALICIA
Drug Class | Penicillin-class Antibacterial Proton Pump Inhibitor Rifamycin Antimycobacterial |
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for TALICIA
US Patents and Regulatory Information for TALICIA
TALICIA is protected by five US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TALICIA is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TALICIA
Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Rifabutin-based compositions and methods for treating Helicobacter pylori infection
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS
Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS
Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS
Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Redhill | TALICIA | amoxicillin; omeprazole magnesium; rifabutin | CAPSULE, DELAYED RELEASE;ORAL | 213004-001 | Nov 1, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Redhill | TALICIA | amoxicillin; omeprazole magnesium; rifabutin | CAPSULE, DELAYED RELEASE;ORAL | 213004-001 | Nov 1, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Redhill | TALICIA | amoxicillin; omeprazole magnesium; rifabutin | CAPSULE, DELAYED RELEASE;ORAL | 213004-001 | Nov 1, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Redhill | TALICIA | amoxicillin; omeprazole magnesium; rifabutin | CAPSULE, DELAYED RELEASE;ORAL | 213004-001 | Nov 1, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Redhill | TALICIA | amoxicillin; omeprazole magnesium; rifabutin | CAPSULE, DELAYED RELEASE;ORAL | 213004-001 | Nov 1, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TALICIA
When does loss-of-exclusivity occur for TALICIA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 14216373
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2015019264
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 00763
Estimated Expiration: ⤷ Try a Trial
Chile
Patent: 15002253
Estimated Expiration: ⤷ Try a Trial
China
Patent: 5163743
Estimated Expiration: ⤷ Try a Trial
Patent: 9893516
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0191559
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 56149
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 56149
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 17645
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 52411
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 0387
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 94529
Estimated Expiration: ⤷ Try a Trial
Patent: 16508516
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 8536
Estimated Expiration: ⤷ Try a Trial
Patent: 15010490
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 1754
Estimated Expiration: ⤷ Try a Trial
Philippines
Patent: 015501783
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 56149
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 56149
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 71400
Estimated Expiration: ⤷ Try a Trial
Patent: 15138708
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 201506318Q
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 56149
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 2062357
Estimated Expiration: ⤷ Try a Trial
Patent: 150118176
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 44406
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 0249
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TALICIA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2956149 | COMPOSITIONS PHARMACEUTIQUES DESTINÉES AU TRAITEMENT D'HELICOBACTER PYLORI (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI) | ⤷ Try a Trial |
Hong Kong | 1217645 | 用於治療幽門螺桿菌的藥物組合物 (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2014127025 | ⤷ Try a Trial | |
Canada | 2900763 | COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT D'HELICOBACTER PYLORI (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI) | ⤷ Try a Trial |
South Korea | 102062357 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |